Multilevel Intervention for Precision Oncology
Conditions
Advanced Cancers of the Prostate, Cancers of the LungSummary
The investigators are rolling out a 3 level intervention designed to improve the use of Precision Oncology at 8 VA medical centers. The 3 components of the intervention are 1: a short educational video for patients, 2: audit and feedback to providers on their Precision Oncology practice patterns, and 3: a change in the electronic medical record to make it easier to order and review results of Precision Oncology tests.
Detailed Description
Background: Precision oncology (PO), the use of molecular testing to identify tumor specific abnormalities which facilitate targeted therapy, is proven to extend lives and improve quality of life for patients with cancer. Extensive study, however, documents that up to 50% of patients in the VA, especially those with adverse social determinants of health (older age, rural), do not receive guideline recommended PO.
Methodology: Building on the investigators’ previous analyses, and the Theoretical Domains Framework, the investigators designed a mixed-methods type I hybrid effectiveness-implementation study of a multilevel intervention (MLI) to improve the use of PO. The MLI will be instituted for veterans with advanced cancers of the colon, lung, and prostate, as well as providers at 8 sites, chosen to represent diversity at the level of rurality, geographic region, cancer volume, and mode of delivery (virtual/in-person). The patient intervention is a 5-minute educational module accessible by QR code. The provider intervention is a 45-minute academic detailing session, as well as individualized audit and feedback on practice patterns. The facility level intervention is a previously piloted integration of PO ordering, interdepartmental communication, and results return into the primary electronic medical record via a consult function. The primary efficacy outcome is the rate of molecular testing/eligible veterans. Validated survey measures will be used for stakeholder engagement. The process evaluation employs a mixed methods approach based in the RE-AIM framework, which includes quantitative analyses of collected data, and interviews of patients and providers. The statistical design is a randomized stepped-wedge trial over 3 years which retains control data from across all sites.
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Contact Person
- Antoinette Vo, BA MA
- 212-686-7500
- [email protected]
Principal Investigator
- Daniel J Becker, MD
Eligibility Criteria
Inclusion Criteria:
* Patients in the VA with cancer of the lung or prostate who are seen in the oncology clinic
Exclusion Criteria:
* Cancer that did not originate in the prostate or the lung
Study Plan
During intervention period
EXPERIMENTAL
All sites will receive the 3 level intervention of patient education, provider audit/feedback, and EMR order change.
OTHER:
Multilevel interventionDescription:
3 components: patient education video, provider audit/feedback, and EMR ordering change
Outcome Measures
Primary Outcome Measures
Use of molecular testing
Secondary Outcome Measures
Use of targeted therapy
Timeline
Last Updated
August 1, 2025Start Date
February 13, 2025Today
October 16, 2025Completion Date ( Estimated )
February 28, 2030
Sponsors of this trial
Lead Sponsor
VA Office of Research and DevelopmentCollaborating Sponsors
VA Madison Health Care, VA Pittsburgh Healthcare System, Martinsburg VA Medical Center, VA Eastern Oklahoma Health Care, New Orleans VA Medical Center, Northport VA Medical Center, Fargo VA Medical Center, VA Iron Mountain Health Care